rockwell medical - RMTI
RMTI
Close Chg Chg %
0.93 0.02 2.54%
Closed Market
0.96
+0.02 (2.54%)
Volume: 125.53K
Last Updated:
Apr 2, 2026, 4:00 PM EDT
Company Overview: rockwell medical - RMTI
RMTI Key Data
| Open $0.93 | Day Range 0.90 - 0.96 |
| 52 Week Range 0.78 - 2.10 | Market Cap $37.83M |
| Shares Outstanding 39.41M | Public Float 34.13M |
| Beta 1.71 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.15 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 299.00K |
RMTI Performance
| 1 Week | 9.96% | ||
| 1 Month | 10.47% | ||
| 3 Months | 10.84% | ||
| 1 Year | -4.31% | ||
| 5 Years | -92.50% |
RMTI Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
2
Full Ratings ➔
About rockwell medical - RMTI
Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. Its products include Triferic, CitraPure, RenalPure and SteriLyte. The company was founded by Robert L. Chioini on October 25, 1996 and is headquartered in Wixom, MI.
RMTI At a Glance
Rockwell Medical, Inc.
30142 South Wixom Road
Wixom, Michigan 48393
| Phone | 1-248-960-9009 | Revenue | 69.26M | |
| Industry | Medical Specialties | Net Income | -5,314,000.00 | |
| Sector | Health Technology | Employees | 157 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
RMTI Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.433 |
| Price to Book Ratio | 0.888 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -6.987 |
| Enterprise Value to Sales | 0.252 |
| Total Debt to Enterprise Value | 0.714 |
RMTI Efficiency
| Revenue/Employee | 441,133.758 |
| Income Per Employee | -33,847.134 |
| Receivables Turnover | 8.505 |
| Total Asset Turnover | 1.19 |
RMTI Liquidity
| Current Ratio | 3.984 |
| Quick Ratio | 3.626 |
| Cash Ratio | 2.609 |
RMTI Profitability
| Gross Margin | 16.886 |
| Operating Margin | -6.773 |
| Pretax Margin | -7.673 |
| Net Margin | -7.673 |
| Return on Assets | -9.134 |
| Return on Equity | -15.277 |
| Return on Total Capital | -10.746 |
| Return on Invested Capital | -11.647 |
RMTI Capital Structure
| Total Debt to Total Equity | 33.725 |
| Total Debt to Total Capital | 25.22 |
| Total Debt to Total Assets | 21.825 |
| Long-Term Debt to Equity | 28.62 |
| Long-Term Debt to Total Capital | 21.402 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Rockwell Medical - RMTI
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 72.81M | 83.61M | 101.49M | 69.26M | |
Sales Growth
| +17.57% | +14.84% | +21.38% | -31.76% | |
Cost of Goods Sold (COGS) incl D&A
| 68.73M | 74.91M | 84.00M | 57.56M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 2.59M | 1.44M | 2.18M | 2.19M | |
Depreciation
| 2.59M | 1.14M | 1.58M | 1.59M | |
Amortization of Intangibles
| - | 300.00K | 600.00K | 600.00K | |
COGS Growth
| +6.81% | +8.98% | +12.14% | -31.48% | |
Gross Income
| 4.08M | 8.70M | 17.48M | 11.70M | |
Gross Income Growth
| +268.47% | +113.49% | +100.87% | -33.11% | |
Gross Profit Margin
| +5.60% | +10.41% | +17.23% | +16.89% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 20.86M | 15.37M | 16.88M | 16.39M | |
Research & Development
| - | 3.12M | 1.11M | 19.00K | |
Other SG&A
| 17.74M | 14.27M | 16.86M | 16.39M | |
SGA Growth
| -25.29% | -26.29% | +9.77% | -2.90% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | - | - |
EBIT after Unusual Expense
| (16.78M) | (6.67M) | 608.00K | (4.69M) | |
Non Operating Income/Expense
| 37.00K | 532.00K | 166.00K | 501.00K | |
Non-Operating Interest Income
| 33.00K | 211.00K | 92.00K | 234.00K | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 1.94M | 2.30M | 1.25M | 1.12M | |
Interest Expense Growth
| -17.97% | +18.85% | -45.50% | -10.37% | |
Gross Interest Expense
| 1.94M | 2.30M | 1.25M | 1.12M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (18.68M) | (8.44M) | (480.00K) | (5.31M) | |
Pretax Income Growth
| +42.83% | +54.82% | +94.31% | -1,007.08% | |
Pretax Margin
| -25.65% | -10.09% | -0.47% | -7.67% | |
Income Tax
| - | - | - | - | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (18.68M) | (8.44M) | (480.00K) | (5.31M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (18.68M) | (8.44M) | (480.00K) | (5.31M) | |
Net Income Growth
| +42.83% | +54.82% | +94.31% | -1,007.08% | |
Net Margin Growth
| -25.65% | -10.09% | -0.47% | -7.67% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (18.68M) | (8.44M) | (480.00K) | (5.31M) | |
Preferred Dividends
| - | - | 302.00K | 153.00K | - |
Net Income Available to Common
| (18.68M) | (8.44M) | (782.00K) | (5.47M) | |
EPS (Basic)
| -1.8931 | -0.3618 | -0.0252 | -0.152 | |
EPS (Basic) Growth
| +50.60% | +80.89% | +93.03% | -503.17% | |
Basic Shares Outstanding
| 9.87M | 23.32M | 31.06M | 35.97M | |
EPS (Diluted)
| -1.8931 | -0.3618 | -0.0252 | -0.152 | |
EPS (Diluted) Growth
| +50.60% | +80.89% | +93.03% | -503.17% | |
Diluted Shares Outstanding
| 9.87M | 23.32M | 31.06M | 35.97M | |
EBITDA
| (14.19M) | (5.23M) | 2.79M | (2.50M) | |
EBITDA Growth
| +48.99% | +63.17% | +153.35% | -189.63% | |
EBITDA Margin
| -19.49% | -6.25% | +2.75% | -3.61% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 3.25 | |
| Number of Ratings | 2 | Current Quarters Estimate | -0.025 | |
| FY Report Date | 06 / 2026 | Current Year's Estimate | -0.075 | |
| Last Quarter’s Earnings | -0.025 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.15 | Next Fiscal Year Estimate | -0.01 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 2 | 2 | 2 | 2 |
| Mean Estimate | -0.03 | -0.02 | -0.08 | -0.01 |
| High Estimates | -0.02 | -0.01 | -0.05 | 0.04 |
| Low Estimate | -0.03 | -0.02 | -0.10 | -0.06 |
| Coefficient of Variance | -28.28 | -47.14 | -47.14 | -707.11 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 2 | 2 | 2 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Rockwell Medical - RMTI
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Rockwell Medical - RMTI
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Apr 16, 2025 | Irrevocable Larson Family Investment Trust | 3,513,000 | Open market or private purchase of non-derivative security Non-derivative transaction at $1.04 per share | 3,653,520.00 |
| Apr 16, 2025 | Irrevocable Larson Family Investment Trust | 3,557,500 | Open market or private purchase of non-derivative security Non-derivative transaction at $1.09 per share | 3,877,675.00 |
| Apr 16, 2025 | Irrevocable Larson Family Investment Trust | 3,532,000 | Open market or private purchase of non-derivative security Non-derivative transaction at $1.07 per share | 3,779,240.00 |
| Apr 16, 2025 | Irrevocable Larson Family Investment Trust | 3,530,000 | Open market or private purchase of non-derivative security Non-derivative transaction at $1.09 per share | 3,847,700.00 |
| Apr 16, 2025 | Irrevocable Larson Family Investment Trust | 3,529,000 | Open market or private purchase of non-derivative security Non-derivative transaction at $1.08 per share | 3,811,320.00 |
| Apr 16, 2025 | Irrevocable Larson Family Investment Trust | 3,527,000 | Open market or private purchase of non-derivative security Non-derivative transaction at $1.09 per share | 3,844,430.00 |
| Apr 16, 2025 | Irrevocable Larson Family Investment Trust | 3,525,000 | Open market or private purchase of non-derivative security Non-derivative transaction at $1.06 per share | 3,736,500.00 |
| Apr 16, 2025 | Irrevocable Larson Family Investment Trust | 3,523,000 | Open market or private purchase of non-derivative security Non-derivative transaction at $1.06 per share | 3,734,380.00 |
| Apr 16, 2025 | Irrevocable Larson Family Investment Trust | 3,521,000 | Open market or private purchase of non-derivative security Non-derivative transaction at $1.06 per share | 3,732,260.00 |
| Apr 16, 2025 | Irrevocable Larson Family Investment Trust | 3,517,000 | Open market or private purchase of non-derivative security Non-derivative transaction at $1.04 per share | 3,657,680.00 |
| Apr 16, 2025 | Irrevocable Larson Family Investment Trust | 3,515,000 | Open market or private purchase of non-derivative security Non-derivative transaction at $1.05 per share | 3,690,750.00 |
| Apr 16, 2025 | Irrevocable Larson Family Investment Trust | 3,474,000 | Open market or private purchase of non-derivative security Non-derivative transaction at $1.06 per share | 3,682,440.00 |
| Apr 16, 2025 | Irrevocable Larson Family Investment Trust | 3,511,000 | Open market or private purchase of non-derivative security Non-derivative transaction at $1.04 per share | 3,651,440.00 |
| Apr 16, 2025 | Irrevocable Larson Family Investment Trust | 3,509,000 | Open market or private purchase of non-derivative security Non-derivative transaction at $1.1 per share | 3,859,900.00 |
| Apr 16, 2025 | Irrevocable Larson Family Investment Trust | 3,499,000 | Open market or private purchase of non-derivative security Non-derivative transaction at $1.07 per share | 3,743,930.00 |
| Apr 16, 2025 | Irrevocable Larson Family Investment Trust | 3,492,000 | Open market or private purchase of non-derivative security Non-derivative transaction at $1.07 per share | 3,736,440.00 |
| Apr 16, 2025 | Irrevocable Larson Family Investment Trust | 3,490,000 | Open market or private purchase of non-derivative security Non-derivative transaction at $1.07 per share | 3,734,300.00 |
| Apr 16, 2025 | Irrevocable Larson Family Investment Trust | 3,484,000 | Open market or private purchase of non-derivative security Non-derivative transaction at $1.08 per share | 3,762,720.00 |
| Apr 16, 2025 | Irrevocable Larson Family Investment Trust | 3,482,000 | Open market or private purchase of non-derivative security Non-derivative transaction at $1.08 per share | 3,760,560.00 |
| Apr 16, 2025 | Irrevocable Larson Family Investment Trust | 3,480,000 | Open market or private purchase of non-derivative security Non-derivative transaction at $1.05 per share | 3,654,000.00 |